Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

Real World Evidence of Daratumumab-Based Treatment in AL Amyloidosis

Charyguly Annageldiyev, Habib Yazgi, Natasha Venugopal, Jorge Raul Vazquez‐Urrutia, Joseph Cioccio, Kentaro Minagawa, Kevin Rakszawski, Natthapol Songdej, Jo Ann Davidson, Shin Mineishi, Seema Naik

Blood (2024) 144 (Supplement 1): 7835.

https://doi.org/10.1182/blood-2024-205270

Published: 2024

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Craig A. Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher M. Reynolds, Priyank P. Patel, Michael J. Robertson, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 733.

https://doi.org/10.1182/blood-2023-182374

Published: 2023

Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 734.

https://doi.org/10.1182/blood-2023-174956

Published: 2023

Journal Articles

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

Blood (2023) 142 (Supplement 1): 4914.

https://doi.org/10.1182/blood-2023-187917

Published: 2023

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Prashasti Agrawal, Kevin A. David, MD, Zhengming Chen, PhD MPH, MS, Suchitra Sundaram, MD, Seo-Hyun Kim, MD, Ryan Vaca, MD, Yong Lin, PhD, Samuel Singer, MD, Mary-Kate Malecek, MD, Jordan Carter, MD, Adam Zayac, MD, Myung Sun Kim, MD, Nishitha Reddy, MD, Alma Habib, MD, Christopher Strouse, MD, Jerome Graber, MD, Veronika Bachanova, MD PhD, Mazie Tsang, MD, Ajay Major, MDMBA, David A. Bond, MD, Angel Mier-Hicks, MD, Pallawi Torka, MD, Priya Rajakumar, MD, Parameswaran Venugopal, MD, Michael Glantz, MD PhD, Samuel Goldlust, MD, Rahul Matnani, MD, Pallavi Kumar, MD, Thomas A Ollila, MD, Johnny Cai, DO, Stephen E. Spurgeon, MD, Alex G Sieg, MD MS, Joseph Cleveland, MD, Narendranath Epperla, MDMS, Reem Karmali, MDMSc, Seema Naik, MD, Sonali M. Smith, MD, James L. Rubenstein, MD PhD, Brad S. Kahl, MD, Amy Chadburn, MD, Andrew M. Evens, DO,MMSc, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-138885

Published: 2020

Journal Articles

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-136551

Published: 2020

Journal Articles

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Adam J Olszewski, MD, Lasse H. Jakobsen, PhD, Graham P. Collins, MD DPhil, Kate Cwynarski, Veronika Bachanova, MD PhD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Mark Bower, MD, Alessia Dalla Pria, MD, Alexey Danilov, MD, Kevin A. David, MD, Catherine Diefenbach, MD, Fredrik Ellin, MD PhD, Narendranath Epperla, MDMS, Umar Farooq, MD, Tatyana A. Feldman, MD, Alina S. Gerrie, MD MPH, Deepa Jagadeesh, MDMPH, Manali Kamdar, MD MD, Reem Karmali, MDMSc, Shireen Kassam, MBBS, FRCPath, PhD, Vaishalee P. Kenkre, MD, Nadia Khan, MD, Andreas Klein, MD, Izidore S. Lossos, MD, Matthew A. Lunning, DO, FACP, Peter Martin, FRCPC, MD MS, Nicolas Martinex-Calle, Silvia Montoto, MD, Seema Naik, MD, Neil Palmisiano, MDMS, David Peace, MD, Elizabeth H Phillips, MBBS, BSc, Tycel J. Phillips, MD, Craig A. Portell, MD, Nishitha Reddy, MD, Anna Santarsieri, MBBS, Maryam Sarraf Yazdy, MD, Knut B. Smeland, Scott E. Smith, MD PhD, Stephen D. Smith, MD, Suchitra Sundaram, MD, Parameswaran Venugopal, MD, Adam Zayac, MD, Xiao-Yin Zhang, PhD, Catherine Zhu, Chan Yoon Cheah, MBBS, Tarec Christoffer El-Galaly, Andrew M. Evens, DO,MMSc

Blood (2020) 136 (Supplement 1): 46–49.

https://doi.org/10.1182/blood-2020-134985

Published: 2020

Journal Articles

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Juan Pablo Alderuccio, MD, Adam J Olszewski, MD, Andrew M. Evens, DO,MMSc, Graham P. Collins, MD DPhil, Alexey Danilov, MD, Mark Bower, MD, Deepa Jagadeesh, MDMPH, Catherine Zhu, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, Suchitra Sundaram, MD, Nishitha Reddy, MD, Alessia Dalla Pria, MD, Christopher D'Angelo, MD, Umar Farooq, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Shireen Kassam, MBBS, FRCPath, PhD, Maryam Sarraf Yazdy, MD, Emma Rabinovich, MD, Frank Post, Gaurav Varma, MDMPH, Reem Karmali, MDMSc, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS,MD, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Agrima Mian, MBBS, MD, Bradley Haverkos, MD MPH, MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Paolo F Caimi, MD, Scott E. Smith, MD PhD, Manali Kamdar, MD, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Daniel Rector, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Craig A. Portell, MD, Yong Lin, PhD, Seema Naik, MD, Silvia Montoto, MD, Izidore S. Lossos, MD, Kate Cwynarski

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-136989

Published: 2020

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Andrew M. Evens, DO, MSc, Alexey Danilov, MD PhD, Deepa Jagadeesh, MDMPH, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, MD MA, Daniel Rector, Suchitra Sundaram, MD, Nishitha Reddy, MD, Yong Lin, PhD, Umar Farooq, MD, Christopher D'Angelo, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Maryam Yazdy, MD, Emma Rabinovich, MD, Gaurav Varma, MD MSPH, Reem Karmali, MD, Agrima Mian, MBBS, MD, Jeremy Ramdial, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Scott E. Smith, MD PhD, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Izidore S. Lossos, MD, Kevin A. David, MD, Seema Naik, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Adam J Olszewski, MD, Juan Pablo Alderuccio, MD

Blood (2019) 134 (Supplement_1): 397.

https://doi.org/10.1182/blood-2019-122971

Published: 2019

Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 5243.

https://doi.org/10.1182/blood-2019-122759

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Christopher J Pizzola, MD MPH, Kevin L Rakszawski, MD, W. Christopher Ehmann, MD, Witold B. Rybka, MD, Baldeep Wirk, MD, Seema Naik, MD, Hong Zheng, MD PhD, Brook Silar, Gina Mackey, CCRP, Shin Mineishi, MD, Kentaro Minagawa, MD PhD, David F. Claxton, MD

Blood (2019) 134 (Supplement_1): 5724.

https://doi.org/10.1182/blood-2019-128817

Published: 2019

Journal Articles

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Chenchen Zhao, MD, Bei Jia, MD PhD, Liru Wang, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2018-99-113547

Published: 2018

Journal Articles

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Bei Jia, MD PhD, Chenchen Zhao, MD, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 5250.

https://doi.org/10.1182/blood-2018-99-113578

Published: 2018

Journal Articles

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

Seema Naik, MD, Paul J. Shaughnessy, MD, Behyar Zoghi, MDPhD, Jose C Cruz, MD, Carlos Bachier, MD

Blood (2015) 126 (23): 1973.

https://doi.org/10.1182/blood.V126.23.1973.1973

Published: 2015

Journal Articles

GATA-1 Protein Levels Are Not Altered in CD34 + and CD61 + Cells, but NF-κb Protein Levels Are Elevated in Patients with Idiopathic Myelofibrosis

Jen-Chin Wang, MD, Seema Naik, MD, Chi Chen, MD, Ph.D, Ying-Yi Xiao, PhD, Tsong H. Chang, MD

Blood (2008) 112 (11): 4498.

https://doi.org/10.1182/blood.V112.11.4498.4498

Published: 2008

NARROW

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real World Evidence of Daratumumab-Based Treatment in AL Amyloidosis

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

GATA-1 Protein Levels Are Not Altered in CD34 + and CD61 + Cells, but NF-κb Protein Levels Are Elevated in Patients with Idiopathic Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only